# Clinical Disease Activity With Long Term Natalizumab Treatment

> **NCT02677077** · — · COMPLETED · sponsor: **Biogen** · enrollment: 277 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT02677077
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2016-08-18
- **Final completion:** 2016-08-18
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02677077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02677077, "Clinical Disease Activity With Long Term Natalizumab Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02677077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*